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Introduction
The extraordinary properties of human Breast milk (BM) can mostly 
be attributed to several bioactive components provided to the breastfed 
neonate in addition to the fundamental nutritional compounds. Human Milk 
Oligosaccharides (HMOs), the third most important solid components of BM 
(the first and the second being lactose and lipids respectively), are a highly 
variable family of unconjugated glycans related to many pathophysiological 
“… the sweetness of it sounds in me, yet.”
Dante Alighieri, The Divine Comedy. Purgatory, Canto II:79-114
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short- and long-term effects on infants [1-3] and, as 
recently demonstrated, even on the mother [4, 5]. 
The HMOs level appears to be higher in colostrum 
and decreases during lactation, especially regarding 
fucosylated compounds [5-7]. In addition, HMOs 
show a higher variability in samples collected 
from mothers who deliver preterm, especially in 
sialylated structures [4, 8].
Owing to HMOs’ great abundance and inter-
individual heterogeneity in BM samples, it would be 
very interesting to investigate the possible benefits 
of their presence in the mother-child dyad [8].
Among their functions are promotion and 
modulation of gut microbiota, effects on intestinal 
mucosa and its development, protection against 
intestinal or extra-intestinal infections, modulation 
of several immune responses and even extra-
intestinal effects, such as brain development, as 
described in literature [4, 6, 9]. 
Infants’ gut microbiota is mostly shaped by BM 
HMOs; in fact, different microbial patterns can be 
detected by comparing BM infants to those fed with 
formula milk (FM) [4, 6, 7].
HMOs are mostly processed in the gut and 
undergo fecal excretion (99%), but a very small 
percentage (1%) can be absorbed and reach many 
target organs through the circulation [1, 5, 8]. 
In the gut, HMOs act as prebiotics, representing 
a selective substrate and a carbon source for 
commensal bacteria such as Bifidobacteria spp., 
Bacteroidetes spp., and Lactobacillus spp. [4, 
9, 10]. 
The metabolites produced by these beneficial 
species can also indirectly influence other microbial 
members (i.e. B. fragilis or E. coli). This interaction, 
as in a “cross-feeding” cascade, can exert several 
metabolic effects; it may promote an infant’s growth 
and determine beneficial effects on many organs 
(such as liver, respiratory and urinary tract and brain, 
including an improvement in neurodevelopment 
and long-term intelligence quotients) [3, 4, 8, 9]. On 
the contrary, the growth of aggressive species, such 
as Enterobacteriaceae or, as recently demonstrated, 
St. agalactiae, is inhibited owing to the inability to 
metabolize HMOs [1, 8].
HMOs also show an effect on the reduction of 
the risk of developing allergies, asthma and other 
diseases, since they act directly and indirectly on 
the infant’s gut mucosal and systemic innate and 
adaptive immunity [1, 10].
HMOs can modulate transcriptional responses 
and improve the barrier function [1, 6] of the 
intestinal epithelium.
As an additional mechanism, the presence in 
BM of extracellular vescicles (EVs) containing 
exosomes and mRNA has recently been proposed. 
This could promote some effects on gut microbiota 
modulation and also influence, immunity and 
growth through not fully clarified mechanisms [11].
Moreover, they can act as soluble decoys because 
of their homology to some intestinal receptors; this 
anti-adhesive antimicrobial activity can lead to the 
elimination of several pathogens, thus preventing 
severe viral, bacterial, protozoan and fungal 
infections [1, 3, 8]. Such an effect, mostly in vitro 
or in animal models, has been demonstrated against 
Norovirus, Rotavirus [1, 4], Calicivirus [5] and 
other pathogens causing diarrhea such as C. jejuni 
and enteropathogenic E. coli, St. pneumoniae, P. 
aeruginosa, or H. influenzae [4] and E. histolytica 
[5], Respiratory syncitial virus and Influenza virus 
[12] and a protective effect against postnatal HIV 
transmission may also occur [3].
Finally, since breastfed preterm newborns show 
a 6- to 10-fold lower risk of developing necrotizing 
enterocolitis if compared with FM fed neonates 
[4], HMOs, in particular 2’fucosyl-lactose (2’FL), 
have been shown to exert a beneficial effect on this 
outcome [8].
In this perspective, HMOs may also act by 
stabilizing the intestinal microbial community, 
modulating epithelial and immune cell responses, 
dealing with leukocyte infiltration and activation 
[13, 14] and improving intestinal blood flow [15].
In addition, there are also several effects on the 
oligosaccharidic fractions caused by the microbiota. 
Intestinal microbes, through diverse interactions 
both among different species and with host-derived 
metabolites and HMOs, contribute to correct gut 
development. Locally, these signaling and in-
flammatory pathways potentially influence the gut, 
as well as distant organs [7, 16].
Utilization of HMOs in the gut, the effects on 
microbiota, the interactions among the host and 
microbial communities (cross feeding) and the 
effects promoted by HMOs on several organs and 
systems are represented in Fig. 1.
Microbiota acts on the HMOs metabolism 
through specific enzymes such as glycosidases, 
transporters and other molecules [1, 4, 8].
Recently, it has been demonstrated that microbial 
community maturation and its stabilization over time 
act differently on HMOs, whose profile in stools 
changes over time in the same patient [5, 8, 17]. 
Regarding HMOs composition, it appears that 
maternal genetic factors play the major role in 
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conferring its high and peculiar inter- and intra-
individual variability to BM [18, 19]. 
HMOs greatly depend on four maternal 
phenotypes, defined depending on the expression 
of two specific genes and maternal blood group. 
The α-1-2-fucosyltransferase (FUT2) gene, 
expressed in more than 70% of Caucasian women, 
is codified by the Se gene and allows classification 
of secretor (Se+) and non-secretor (Se-) mothers. 
In addition, the α-1-3-4-fucosyltransferase (FUT3) 
gene indicates positivity or negativity for the Lewis 
Group (Le+ or Le-) [1, 4, 19-21].
In the BM collected from Se+/Le+ mothers, all the 
fucosylated oligosaccharides can be detected (2’FL, 
lactodifucotetraose LDFT, lacto-N-fucopentaose 
I LNFPI, lactodifucoesaose I LNDFHI). On the 
contrary, the Se-/Le+ mothers’ phenotype determines 
the presence of HMOs with (α1-3)- and (α1-4)-
linked fucose residues [1, 4, 6, 19]. 
Even other environmental and maternal factors, 
represented by age, diet, health status, medication 
and drugs appear to play a role in HMOs composi-
tion [l].
Moreover, we previously underlined briefly the 
importance of a metabolomic approach in defining 
HMOs; our preliminary data would suggest that the 
human milk metabolome does not depend on infant 
gender, delivery mode and/or birth weight [19].
Finally, although on a small sample of patients, 
Smith-Brown et al. [22] demonstrated that the 
beneficial influence of maternal secretor status on 
gut microbiota composition can also persist after 
2-3 years from suspension of breastfeeding.
In conclusion, since BM oligosaccharide 
composition varies in each mother, it can exert a 
different influence on microbiota, thus modulating 
the short- and long-term outcome of the infant in 
several ways [1].
Figure 1. Utilization of Human Milk Oligosaccharides (HMOs) in the gut. Effects on microbiota and interactions among the 
host and microbial communities (cross feeding). Effects promoted by HMOs on several organs and systems.
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In addition to intestinal microbes, HMOs may 
also influence extra-intestinal microbial com-
munities; therefore, the maternal “lactobiome” may 
cause different systemic effects both in the newborn 
and on the lactating mother [5]. 
Improved knowledge of all these aspects will 
help in developing more suitable dietary foods 
for infant nutrition with the closest similarity to 
BM, both in terms of composition and functions 
[14]. Up to now, supplementation with key human 
milk glycans appears very promising and 2’FL is 
considered a safe additive for human nutrition. 
The introduction of sialylated oligosaccharides 
has recently been proposed as an efficacious strategy 
against undernutrition and growth impairment 
[9, 23].
However, more studies are needed to clarify the 
complexity of the HMOs structure and interactions 
and also to evaluate the reliability of the potential 
benefits related to their supplementation in the 
infant diet [14].
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